blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2239580

EP2239580 - Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.01.2014
Database last updated on 25.09.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
LGA BIOTECNOLOGIE SRL
Via Firenze 40
20060 Trezzano Rosa (MI) / IT
[2012/07]
Former [2011/14]For all designated states
Sofar SPA
Via Firenze 40
20060 Trezzano Rosa (MI) / IT
Former [2010/41]For all designated states
Sofar SPA
Viale Isonzo, 8
20135 Milano / IT
Inventor(s)01 / Grande, Alexis
Via dei Glicini, 61/4
41100 Modena / IT
02 / Parenti, Sandra
Via Firenze, 198
41100 Modena / IT
03 / Ferrarini, Fabrizio
Via Ventimiglia, 121
41100 Modena / IT
 [2010/41]
Representative(s)Pistolesi, Roberto, et al
Dragotti & Associati Srl
Via Nino Bixio, 7
20129 Milano / IT
[2013/13]
Former [2010/41]Pistolesi, Roberto, et al
Dragotti & Associati Srl Via Marina 6
20121 Milano / IT
Application number, filing date09425136.009.04.2009
[2010/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2239580
Date:13.10.2010
Language:EN
[2010/41]
Type: B1 Patent specification 
No.:EP2239580
Date:27.03.2013
Language:EN
[2013/13]
Search report(s)(Supplementary) European search report - dispatched on:EP11.11.2009
ClassificationIPC:C12Q1/68, G01N33/574
[2012/40]
CPC:
G01N33/57419 (EP,US); C12Q1/6886 (EP,US); C12Q2600/106 (EP,US);
C12Q2600/158 (EP,US); G01N2333/705 (EP,US)
Former IPC [2010/41]G01N33/574
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/41]
Extension statesAL11.04.2011
BA11.04.2011
RS11.04.2011
TitleGerman:Bestimmung von 5-ASA-Wirksamkeit bei der Verhinderung und/oder Behandlung von kolorektalem Krebs durch Genexpressionsanalyse[2010/41]
English:Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis[2010/41]
French:Détermination de l'efficacité du 5-ASA pour la prévention et/ou le traitement du CRC par l'analyse de l'expression génique[2010/41]
Examination procedure11.04.2011Amendment by applicant (claims and/or description)
11.04.2011Examination requested  [2011/25]
25.07.2011Despatch of a communication from the examining division (Time limit: M06)
22.12.2011Reply to a communication from the examining division
24.01.2012Despatch of a communication from the examining division (Time limit: M04)
16.05.2012Reply to a communication from the examining division
05.11.2012Communication of intention to grant the patent
12.02.2013Fee for grant paid
12.02.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.07.2011
Opposition(s)03.01.2014No opposition filed within time limit [2014/10]
Fees paidRenewal fee
26.04.2011Renewal fee patent year 03
26.04.2012Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.04.2009
AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
DK27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
MK27.03.2013
MT27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
TR27.03.2013
IE09.04.2013
LU09.04.2013
CH30.04.2013
LI30.04.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
[2015/34]
Former [2015/32]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
DK27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
MK27.03.2013
MT27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
TR27.03.2013
IE09.04.2013
CH30.04.2013
LI30.04.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2015/13]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
DK27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
MT27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
IE09.04.2013
CH30.04.2013
LI30.04.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2014/20]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
DK27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
IE09.04.2013
CH30.04.2013
LI30.04.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2014/09]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
DK27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
CH30.04.2013
LI30.04.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2014/08]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
CH30.04.2013
LI30.04.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2014/03]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
MC27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2013/52]AT27.03.2013
BE27.03.2013
CY27.03.2013
CZ27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2013/50]AT27.03.2013
BE27.03.2013
CZ27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
PL27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2013/49]AT27.03.2013
BE27.03.2013
CZ27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
SE27.03.2013
SI27.03.2013
SK27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2013/48]AT27.03.2013
BE27.03.2013
EE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
SE27.03.2013
SI27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
IS27.07.2013
PT29.07.2013
Former [2013/47]BE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
SE27.03.2013
SI27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
PT29.07.2013
Former [2013/44]BE27.03.2013
FI27.03.2013
HR27.03.2013
LV27.03.2013
SE27.03.2013
SI27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
Former [2013/41]FI27.03.2013
HR27.03.2013
LV27.03.2013
SE27.03.2013
SI27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
Former [2013/38]FI27.03.2013
LV27.03.2013
SE27.03.2013
SI27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
Former [2013/37]FI27.03.2013
SE27.03.2013
SI27.03.2013
BG27.06.2013
NO27.06.2013
GR28.06.2013
Former [2013/34]SE27.03.2013
BG27.06.2013
NO27.06.2013
Former [2013/33]NO27.06.2013
Documents cited:Search[XA]  - BOS CARINA L ET AL, "Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.", CARCINOGENESIS DEC 2006, (200612), vol. 27, no. 12, ISSN 0143-3334, pages 2371 - 2382, XP002539164 [X] 1-3,5-8 * abstract * * figures 1-3 * * page 2372, cell culture paragraph * [A] 4

DOI:   http://dx.doi.org/10.1093/CARCIN/BG1071
 [A]  - RUBIN DAVID T ET AL, "Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.", INFLAMMATORY BOWEL DISEASES FEB 2008, (200802), vol. 14, no. 2, ISSN 1078-0998, pages 265 - 274, XP002539165 [A] 1-8 * page 271, column L, paragraph 2 *

DOI:   http://dx.doi.org/10.1002/ibd.20297
 [A]  - STOLFI CARMINE ET AL, "Molecular basis of the potential of mesalazine to prevent colorectal cancer.", WORLD JOURNAL OF GASTROENTEROLOGY : WJG 28 JUL 2008, (20080728), vol. 14, no. 28, ISSN 1007-9327, pages 4434 - 4439, XP002539166 [A] 1-8 * figure 1 * * page 4436, column R, paragraph 2 - page 4437, column L, paragraph 2 *

DOI:   http://dx.doi.org/10.3748/WJG.14.4434
 [A]  - GOLDBERG M ET AL, "mu.-protocadherin, a novel developmentally regulated protocadherin with mucin-like domains", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, (20000811), vol. 275, no. 32, ISSN 0021-9258, pages 24622 - 24629, XP002974003 [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M000234200
by applicant   - JANNE PA; MAYER RJ., "Chemoprevention of colorectal cancer", N ENGL J MED, (2000), vol. 342, pages 1960 - 8
    - SANDLER RS ET AL., "A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.", N ENGL J MED, (2003), vol. 348, pages 883 - 90
    - STOLFI C ET AL., "Molecular basis of the potential of mesalazine to prevent colorectal cancer.", WORLD J GASTROENTEROL, (2008), vol. 14, pages 4434 - 9
    - CHENG Y; DESREUMAUX P., "5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.", WORLD J GASTROENTEROL, (2005), vol. 11, pages 309 - 14
    - ALLGAYER H., "Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.", ALIMENT PHARMACOL THER, (2003), vol. 18, no. 2, pages 10 - 4
    - ROUSSEAUX C ET AL., "Intestinal antiinflammatory effect of 5- aminosalicylic acid is dependent on peroxisome proliferator-activated receptor- gamma.", J EXP MED, (2005), vol. 201, pages 1205 - 15
    - REINACHER-SCHICK A ET AL., "Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells.", CARCINOGENESIS, (2003), vol. 24, pages 443 - 51
    - GASCHE C ET AL., "Mesalazine improves replication fidelity in cultured colorectal cells.", CANCER RES, (2005), vol. 65, pages 3993 - 7
    - CHU EC ET AL., "Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?", ALIMENT PHARMACOL THER, (2007), vol. 25, pages 1443 - 9
    - LUCIANI MG ET AL., "5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint.", GASTROENTEROLOGY, (2007), vol. 132, pages 221 - 35
    - BOS CL ET AL., "Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.", CARCINOGENESIS, (2006), vol. 27, pages 2371 - 82
    - VAN DE WETERING M ET AL., "The beta- catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.", CELL, (2002), vol. 111, pages 241 - 50
    - FEVR T ET AL., "Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells.", MOL CELL BIOL, (2007), vol. 27, pages 7551 - 9
    - OLMEDA D ET AL., "Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis.", MOL BIOL CELL, (2003), vol. 14, pages 2844 - 60
    - AOKI K ET AL., "Chromosomal instability by beta-cateninlTCF transcription in APC or beta-catenin mutant cells.", ONCOGENE, (2007), vol. 26, pages 3511 - 20
    - PALMER HG ET AL., "Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling.", J CELL BIOL, (2001), vol. 154, pages 369 - 87
    - HOU R ET AL., "The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals.", J CELL BIOL, (2006), vol. 173, pages 417 - 29
    - EVANS PM; LIU C., "Roles of Krüpel-like factor 4 in normal homeostasis, cancer and stem cells", ACTA BIOCHIM BIOPHYS SIN (SHANGHAI), (200807), vol. 40, no. 7, pages 554 - 64
    - ZHANG W ET AL., "Novel cross talk of Kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor repression.", MOL CELL BIOL., (200603), vol. 26, no. 6, pages 2055 - 64
    - SCHUSTER MB; PORSE BT., "C/EBPalpha: a tumour suppressor in multiple tissues?", BIOCHIM BIOPHYS ACTA, (200608), vol. 1766, no. 1, pages 88 - 103
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.